The visual analogue scale (VAS) is a standard measurement tool in pain research and clinical practice, and has been shown to have linear scale properties for mild to moderate pain. Our aim was to evaluate the scaling properties of the VAS in subjects with severe acute pain. After Ethics Committee approval we studied 22 patients and asked them to rate the severity of their pain on a 100 mm VAS at the initial assessment (VAS 1 ), and again after administration of analgesic medication. The subject was asked to nominate when they considered their pain intensity had halved, and at this time they were asked to rate this on a second VAS (VAS 0.5 ). When the subject had received satisfactory relief of their pain, they were asked to describe how much their pain had been relieved and were then asked to rate their final pain state using a third VAS (VAS final ). The mean (SD) scores were VAS 1 84 (14) (range 56-100), VAS 0.5 42 (13) and VAS final 21 (16). The mean (95% CI) for VASratio was 0.51 (0.45-0.57). The mean (SD) patients' estimate of pain relief was 77 (21)% from that of baseline, with a mean (SD) VAS final 0.26 (0.20),. The correlation of the patients' estimate of pain relief with the VAS final was r=0.89, rho=0.87, both P<0.001. The VAS is a linear scale in subjects with severe acute pain. Changes in the VAS score represent a relative change in the magnitude of pain sensation.
Clinical practice guidelines recommend frequent measurement of pain intensity in order to optimize treatment 1 . Despite pain being acknowledged as a multi-dimensional experience, it is commonly assessed with only one of several unidimensional scales. Perhaps the most common is the visual analogue scale (VAS), which has become a standard measurement tool in pain research and clinical practice [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The VAS was initially developed to evaluate patients with chronic pain, but it has frequently been used to measure acute pain, particularly acute postoperative pain. Pain intensity is rated on a 100 mm horizontal line and is measured from the left boundary as a VAS score in millimetres or centi-metres. The VAS score correlates well with acute pain levels [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , although it has a measurement error of about 15 to 20 mm 3, 7, 8 .
The meaning of a change in the pain intensity should be evaluated by asking the patient to rate simultaneously the change in the VAS score and the degree of pain relief 14, 17, 18 .
We have previously demonstrated that the VAS had linear scale properties in patients with mild to moderate pain after surgery, and concluded that the VAS score can be considered as ratio data for statistical analysis and interpretation 14 . Patients with severe pain need immediate assessment and treatment, and such assessment should be quantifiable. We therefore tested the hypothesis that the VAS score is a linear measurement of severe acute pain.
METHODS
After Ethics Committee approval we approached subjects who had severe pain and were requesting pain relief. Potentially eligible subjects were asked to confirm their pain intensity, and in all cases rated this as "severe". The study population consisted of two discrete cohorts: (i) male and female patients recovering from surgery, with pain at rest, and (ii) women during labour. Both were included in the primary analysis, in order to explore whether or not the psychometric properties of the VAS varied in different acute pain conditions. Patients who were unable to complete the VAS, for example those with postoperative delirium, frailty or visual impairment, were excluded.
When first approached, we asked patients to rate the severity of their pain on a VAS whilst commencing appropriate management of their pain, the details of which are presented below. We then provided a brief explanation of the study to them and obtained verbal agreement to proceed with further measurements. After pain relief had been obtained and the subject was deemed to have recovered from their pain state, we provided a complete written and verbal explanation of the study to them and obtained retrospective informed consent. Benzodiazepines were not administered immediately before or during the study.
Methods of Pain Relief
All subjects were requesting immediate pain relief. Patients managed with intravenous (IV) analgesia were given incremental doses of IV fentanyl, 25-50 µg; those with an epidural catheter in situ were given a 4-8 ml bolus dose of bupivacaine 0.125-0.5%, and had their rate of infusion of 0.125% bupivacaine plus fentanyl 2 µg/ml adjusted. Women in labour had an epidural catheter inserted, and a 5-15 ml bolus dose of 0.125% bupivacaine plus fentanyl 2 µg/ml administered.
Pain VAS Measurements
Each subject was assessed by one of the investigators and had their current pain measured using the 100 mm VAS. The line was unmarked, and ends were marked with "no pain" and "worst pain ever". We called this existing pain rating VAS 1 . The subject was asked to designate when they considered their pain intensity had halved, and at this time they were asked to rate this on a second VAS (VAS 0.5 ). When the subject had received satisfactory pain relief, they were asked to describe how much their pain had been relieved and were then asked to rate their final pain state using a third VAS (VAS final ). Both the VAS 0.5 and the VAS final were presented on separate sheets, after concealing their earlier VAS rating(s). The ratios of VAS 0.5 to VAS 1 (VAS ratio ) and VAS final to VAS 1 (VAS ratio2 ) were calculated.
Pooled Study Data
The generalizability of the study was extended by including data from our previous study 14 . We classified patients from this earlier study as having severe pain if they had a VAS >55 mm 12 , and included this cohort with our present study data in a second analysis (Table 1) . Finally, we included all subjects in both study cohorts in a final analysis in order to maximize the precision of our estimates.
Statistical Analysis
Our sample size was based on a previous study 14 and clinical observations in patients with moderateto-severe pain. We anticipated a mean (standard deviation [SD]) VAS ratio of 0.5 (0.1) in patients with severe pain. A preliminary estimate of sample size was based on a 95% confidence interval (CI) for the VAS ratio including values within a clinically acceptable range, defined as 0.42-0.58. A sample size of 20 patients had a type I error of 0.05 and a type II error of 0.20.
Descriptive data and VAS pain scores are presented as median (interquartile range [IQR] or range) and/or mean (SD). Testing for whether the VAS data and ratios were consistent with sampling from a normal distribution was performed using visual inspection of the sample frequency distributions (results not presented, but available from the authors) and the Kolmogorov-Smirnov test (all P>0.50). Logarithmic transformation did not alter the variance:mean relationship, signifying a uniform variance between groups 19 . These procedures supported treating the VAS ratio as normally distributed numerical data. The ratios are presented as mean (CI). Correlation coefficients, Pearson r and Spearman rank rho, were used as measures of association. An exploratory multivariate linear regression analysis was also done. All statistical analyses were performed using SPSS for Windows V11.1 (SPSS Ltd, Chicago, IL). A P value <0.05 was considered statistically significant.
RESULTS

Present Study
We approached 22 eligible subjects and all were subsequently recruited ( Table 1) . They had a mean (SD) age of 33 (17) years (range 17-81 years). Postoperative patients were assessed at 0.4 (0.2-6.3) hours after their surgery. Patients receiving IV fentanyl (n=10) required 88 (50-100) µg, and those with epidural analgesia (n=12) required 13 (11-15) ml, to achieve satisfactory pain relief.
The mean (SD) and median (IQR) VAS 1 scores were 84 (14) mm and 83 (77-99), respectively. The mean (SD) and median (IQR) VAS 0.5 scores were 42 (13) mm and 42 (35-52). Corresponding scores for VAS final were 21 (16) and 20 (10-28) mm. The mean (CI) for VAS ratio was 0.51 (0.45-0.57).
The mean (SD) patients' estimate of pain relief was 77 (21)% from that of baseline, with a mean (SD) VAS ratio2 0.26 (0.20), CI 0.17-0.38. The correlation of the patient's estimate of pain relief with the VAS ratio2 was r=0.89, rho=0.87, both P<0.001. A regression analysis identified the patients' estimate of pain relief (P<0.001) and ASA status (P=0.006), but not patient age (P=0.06), gender (P=0.64) or source of pain (P=0.58), as significant correlates of VAS ratio2 ; model R 2 =0.88. The median VAS ratio2 for ASA I, II, II and IV patients were 0.47, 0.53, 0.36, and 0.37, respectively.
The relationships between pain relief and VAS for individual patients are presented in Figure 1 . The relationship between the patients' description of their pain relief and VAS ratio2 is presented in Figure 2 .
Pooled Data (i) Severe pain cohort
Of the 52 patients enrolled in our previous study, 16 (31%) had severe pain at baseline, so that the severe pain cohort consisted of 38 patients ( Table 1) . The mean (SD) VAS 1 score was 76 (16) mm (range 55-100 mm), consistent with severe pain. The mean (SD) and median (IQR) VAS 0.5 scores were 38 (13) mm and 38 (29-44) mm. The mean (CI) for VAS ratio was 0.50 (0.46-0.54).
(ii) All patients
The pooled study cohort consisted of 74 patients ( Table 1 ). The mean (SD) VAS 1 score was 55 (27) mm (range 8-100 mm), reflecting a broad range of pain intensity. The 25th centile VAS score was 29 mm, 50th centile score 55 mm, and 75th centile score 78 mm. The mean (SD) and median (IQR) VAS 0.5 scores were 26 (17) mm and 24 (12-39) mm. The mean (CI) for VAS ratio was 0.47 (0.41-0.52). A graphical representation of the pooled data describing the relationship between the patient's description of their pain relief and VAS ratio2 is presented in Figure 3 .
DISCUSSION
We have shown that the VAS has properties consistent with a linear scale in subjects with severe acute pain. When combined with our previous study 14 , we have now demonstrated that the pain VAS score is linear for all degrees of acute pain intensity. A change in the VAS score represents a relative change in the magnitude of pain intensity for all patients with acute pain. This means that if a treatment leads to a change in VAS score from 60 mm to 20 mm, then this represents a 66% reduction in pain intensity. Similarly, a 40% reduction in VAS score represents a 40% reduction in pain intensity. This offers a useful quantification of treatment effect in pain studies, including analgesic drug and other intervention trials.
In a number of analgesic studies, percentage changes in VAS have been used in the definition of a positive effect. The proportion of patients achieving a desired level of pain relief is more clinically relevant than the average fall in VAS in studies evaluating pain interventions. Previous authors 20 have suggested a 50% reduction in baseline VAS represents a meaningful analgesic effect. Others have found that a change in VAS of about 20 mm represented satisfactory pain relief in patients after surgery 7 , or that the minimal change in acute postoperative pain, rated on an 11-point scale, that is clinically significant is 20% 18. In the latter study a reduction in pain of 35% corresponded to "much" improvement and 45% corresponded to "very much" improvement in pain 18 . Studies using the VAS have found comparable results 7, 16 . Others have studied the relationship between the pain VAS score and morphine requirements in patients after surgery [16] [17] [18] . One study found a sigmoid relationship between the pain VAS score and morphine administration, typical of a dose-response curve 16 . This is consistent with the pain VAS score being a linear scale 21 .
The scale properties of the pain VAS score found in our study support use of parametric statistical tests when analysing VAS scores and this is supported by other studies [22] [23] [24] . There is some additional evidence supporting the linearity and ratio scale properties of the VAS. In a study of patients with chronic orofacial pain, using repeat application to the forearm of different levels of noxious thermal stimuli (45-51 degrees C), VAS scores predicted temperatures chosen and so provided evidence for ratio scale properties of the VAS 25 .
There are several limitations of this study. Participants may have intuitively believed that the pain VAS is a linear scale and, therefore, attempted to halve their scores based on their recollection of their first VAS assessment. We sought to minimize this potential source of bias by clear patient explanation and concealment of their previous responses. There is evidence that patients are not necessarily influenced by previous ratings when asked to repeat measurements 11, 15 . Others have reported a relatively modest correlation with repeat measurements of a stable pain state 7 . Our pooled analysis included a variety of patients with variable acute pain states; the heterogeneity testing (source of pain, P=0.58) and the study findings support the generalizability of the results.
The VAS is a unimodal measure of pain intensity and cannot adequately represent all aspects of pain perception. In addition, its ability to represent changes in pain intensity during analgesic administration, particularly rapid changes associated with epidural analgesia, may not be ideal. The extremes of pain -"no pain" and "worst pain ever" -may not truly represent absolute limits of perception. Despite this, the simplicity for patients, clinicians and researchers, as well as the reliability and reproducibility of the VAS, make it a widely used and validated form of pain measurement.
We have shown that in patients with acute pain after surgery, and women in labour, the VAS score is a linear scale. Changes in the VAS score represent relative changes in the magnitude of pain sensation. 
